Dose-escalated pelvic radiotherapy for prostate cancer in definitive or postoperative setting

[1] Moris L(2020)Benefits and risks of primary treatments for high-risk localized and locally advanced prostate cancer: an international multidisciplinary systematic review [formula presented] Eur Urol 77 614-627

[2] Cumberbatch MG(2019)A systematic review of the role of definitive local treatment in patients with clinically lymph node-positive prostate cancer Eur Urol Oncol 2 294-301

[3] Van den Broeck T(2014)The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study Int J Radiat Oncol Biol Phys 88 1064-1073

[4] Gandaglia G(2013)Radiation therapy for clinically node-positive prostate adenocarcinoma is correlated with improved overall and prostate cancer-specific survival Pract Radiat Oncol 3 234-240

[5] Fossati N(2016)Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer JAMA Oncol 2 348-357

[6] Kelly B(2018)Efficacy of local treatment in prostate cancer patients with clinically pelvic lymph node-positive disease at initial diagnosis Eur Urol 73 452-461

[7] Ventimiglia E(2015)Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer J Natl Cancer Inst 107 1-10

[8] Seisen T(2016)Ten- and 15-yr prostate cancer-specific mortality in patients with nonmetastatic locally advanced or aggressive intermediate prostate cancer, randomized to lifelong endocrine treatment alone or combined with radiotherapy: final results of The Scandinavian Eur Urol 70 684-691

[9] Abdollah F(2011)Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial Lancet 378 2104-2111

[10] Briganti A(2015)Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer J Clin Oncol 33 2143-2150

[1] Moris L(2020)Benefits and risks of primary treatments for high-risk localized and locally advanced prostate cancer: an international multidisciplinary systematic review [formula presented] Eur Urol 77 614-627

[2] Cumberbatch MG(2019)A systematic review of the role of definitive local treatment in patients with clinically lymph node-positive prostate cancer Eur Urol Oncol 2 294-301

[3] Van den Broeck T(2014)The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study Int J Radiat Oncol Biol Phys 88 1064-1073

[4] Gandaglia G(2013)Radiation therapy for clinically node-positive prostate adenocarcinoma is correlated with improved overall and prostate cancer-specific survival Pract Radiat Oncol 3 234-240

[5] Fossati N(2016)Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer JAMA Oncol 2 348-357

[6] Kelly B(2018)Efficacy of local treatment in prostate cancer patients with clinically pelvic lymph node-positive disease at initial diagnosis Eur Urol 73 452-461

[7] Ventimiglia E(2015)Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer J Natl Cancer Inst 107 1-10

[8] Seisen T(2016)Ten- and 15-yr prostate cancer-specific mortality in patients with nonmetastatic locally advanced or aggressive intermediate prostate cancer, randomized to lifelong endocrine treatment alone or combined with radiotherapy: final results of The Scandinavian Eur Urol 70 684-691

[9] Abdollah F(2011)Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial Lancet 378 2104-2111

[10] Briganti A(2015)Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer J Clin Oncol 33 2143-2150